Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/1993
10/28/1993WO1993020691A1 Method for inducing tumor immunity
10/28/1993WO1993017115A3 Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it
10/28/1993WO1993014206A3 Synthetic peptides for a rubella vaccine
10/28/1993WO1993013797A3 Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
10/28/1993CA2388198A1 Adrenocorticotropic hormone receptor and uses
10/28/1993CA2133999A1 Recombinant mutants for inducing specific immune responses
10/28/1993CA2133749A1 Suppression of t-cell proliferation using peptide fragments of myelin basic protein
10/28/1993CA2133739A1 Immunotoxins directed against c-erbb-2 (her-2/neu) related surface antigens
10/28/1993CA2133339A1 Wild-type measles virus glycoproteins: vaccine and detection method therefor
10/28/1993CA2131166A1 Peptides having a gdp exchange factor activity, nucleic acid sequences coding for said peptides, preparation and utilization
10/28/1993CA2118502A1 Supression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides
10/28/1993CA2118234A1 Genetically engineered attenuated viruses
10/28/1993CA2118123A1 Method for inducing tumor immunity
10/28/1993CA2118033A1 Synthetic polypeptides derived from the hiv envelope gylcoprotein
10/28/1993CA2118026A1 Induction of ctl responses
10/28/1993CA2117887A1 Polysaccharide binding fusion proteins and conjugates
10/28/1993CA2117779A1 T cell epitopes of the major allergens from ambrosia artemisifolia
10/28/1993CA2117775A1 Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
10/28/1993CA2117770A1 Substituted thioureas as bifunctional chelators
10/28/1993CA2111189A1 Oral treatment of helicobacter infection
10/27/1993EP0567100A1 Mutant respiratory syncytial virus (RSV) vaccines containing same and methods of use
10/27/1993EP0566698A1 Amino-substituted pyrimidines, derivatives and methods of use therefor
10/27/1993EP0566647A1 Improved humanized immunoglobulins
10/27/1993EP0566611A1 Analogs of piscine lhrh
10/27/1993CN1022570C Process for preparing antiviral compounds
10/26/1993US5256771 Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
10/26/1993US5256766 Recombinant thrombin receptor and related pharmaceuticals
10/26/1993US5256641 Covalent polar lipid-peptide conjugates for immunological targeting
10/26/1993US5256415 Vaccine against bovine respiratory disease (pasteurellosis)
10/26/1993US5256411 Immune cell proliferation inhibitors
10/26/1993US5256406 Treatment of hair loss and dermatological problems
10/26/1993US5256395 Drug delivery by administering a receptor binding assay having a dual preferential monoclonal antibody conjugating with predetermined haptens
10/26/1993CA1323728C Human gamma interferon-specific receptor protein, antibody against said protein, methods for obtaining said protein and said antibody and compositions containing said protein and antibody
10/26/1993CA1323567C Method for purification of antibodies
10/26/1993CA1323566C Biodegradable polymeric drug delivery system with adjuvant activity
10/26/1993CA1323565C Method and agents for removing advanced glycosylation endproducts
10/26/1993CA1323564C Low dosage of interferon to enhance vaccine efficiency
10/21/1993CA2093735A1 Amyloid precursor-like protein and uses thereof
10/20/1993EP0566166A1 Chelants possessing ortho ligating functionality and complexes thereof
10/20/1993EP0566066A1 Antigens of human non-small lung carcinoma
10/20/1993EP0565978A1 Artivated carriers, their fabrication and use
10/20/1993EP0565794A1 Induction of CTL responses
10/20/1993EP0565708A1 Vaccine against pathogens of mucosae using liposomes
10/20/1993EP0565642A1 Method of preventing inflammatory damage
10/20/1993EP0565626A1 Fusions of a viral protein and a destructive enzyme
10/20/1993EP0565590A1 ADHESIN-OLIGOSACCHARIDE CONJUGATE VACCINE FOR $i(HAEMOPHILUS INFLUENZAE)
10/20/1993EP0480982B1 Vaccines and vectors with liquid active principles containing an oil which can be metabolised
10/20/1993EP0480981B1 Injectable multi-phase emulsions
10/20/1993EP0220241B1 Purified protein having angiogenic activity and methods of preparation
10/20/1993CN1077390A Thrombolyzing medicine and its prepn.
10/19/1993US5254672 Synthetic peptides which contain sequences from factor VIIa, and the use thereof
10/19/1993US5254671 Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
10/19/1993US5254593 Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking
10/19/1993US5254459 Nucleotide and amino acid sequences of protein MTP40 of M. tuberculosis and synthetic peptides derived therefrom
10/19/1993US5254340 Vaccine suitable for prophylaxis and control, respectively, of the pig disease caused by Haemophilus pleuropneumoniae and a method for obtaining extracellular proteinaceous material of Haemophilus pleuropneumoniae for use in such vaccines
10/19/1993US5254339 Solubilizing antigen; complexing with glycosides containing hydrophobic and hydrophilic domains; isolation; purification
10/19/1993CA1323304C Immunization against parasitic protozoa
10/19/1993CA1323303C Advanced anticancer therapy and cytotoxic medicaments for its implementation
10/19/1993CA1323302C Vaccine enhanced by interferon
10/15/1993CA2093866A1 Methods of inhibiting the growth of multidrug resistant tumors
10/14/1993WO1993020439A1 Compositions and methods for regulating cellular signal transducing systems
10/14/1993WO1993020220A1 Non-infectious hiv particles and uses therefor
10/14/1993WO1993020212A1 METHOD OF ELIMINATING INHIBITORY/INSTABILITY REGIONS OF mRNA
10/14/1993WO1993020210A1 Antibodies for treatment and prevention of respiratory syncytial virus infection
10/14/1993WO1993020197A1 Stem cell proliferation factor
10/14/1993WO1993020189A1 Process for the production of a viable cell culture infected by a multiple sclerosis associated virus
10/14/1993WO1993020188A1 Process and culture medium for the production of cells infected by a multiple sclerosis associated virus
10/14/1993WO1993020187A1 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
10/14/1993WO1993020186A1 In vitro generation of human dendritic cells and uses thereof
10/14/1993WO1993020185A1 Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
10/14/1993WO1993020103A2 Peptides of an antigen, capable of recognition by or induction of cytotoxic t lymphocytes, and method of their identification
10/14/1993WO1993020079A1 Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
10/14/1993WO1993020076A1 Catalytic antibodies against cocaine and methods of using and producing same
10/14/1993WO1993020070A1 Novel tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels
10/14/1993WO1993020067A1 Benzodiazepine derivatives and protein and polypeptide conjugates thereof
10/14/1993WO1993020064A1 Novel barbiturate derivatives and protein and polypeptide barbiturate derivative conjugates and labels
10/14/1993WO1993020049A1 Novel phencyclidine derivatives and protein and polypeptide phencyclidine derivative conjugates and labels
10/14/1993WO1993020048A1 Novel amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels
10/14/1993WO1993019785A1 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection
10/14/1993WO1993019782A1 Specific detection of cell surface receptor leukocyte adhesion molecule-1
10/14/1993WO1993019781A1 Vaccines containing non-ionic surfactant vesicles
10/14/1993WO1993019780A1 Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a
10/14/1993WO1993019779A1 Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
10/14/1993WO1993019778A1 Method for inducing tolerance to an antigen using butyrate
10/14/1993WO1993019775A1 Administration of liposomes containing peptides or proteins including ctl eptitopes of hiv proteins
10/14/1993WO1993019769A1 Wound healing and treatment of fibrotic disorders
10/14/1993WO1993019767A1 Cd28 pathway immunoregulation
10/14/1993WO1993019766A1 Methods and compositions for restoring impaired cellular immune function
10/14/1993WO1993019761A1 Lipid-a analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
10/14/1993WO1993019668A1 Method and kit for imaging and treating organs and tissues
10/14/1993WO1993019605A1 Evaluation and treatment of patients with progressive immunosuppression
10/14/1993WO1993019603A1 Prokaryotes including dna encoding bacteriophage immunity
10/14/1993WO1993019591A1 Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
10/14/1993WO1993017118A3 Defective packaging non-oncoviral vectors based on mpmv and hiv
10/14/1993WO1993017110A3 A recombinant hepatitis c virus polypeptide
10/14/1993WO1993014208A3 Hepatitis e virus vaccine and method
10/14/1993CA2133662A1 Antibodies for treatment and prevention of respiratory syncytial virus infection
10/14/1993CA2133075A1 CD28 Pathway Immunoregulation
10/14/1993CA2132624A1 Compositions and methods for regulating cellular signal transducing systems
10/14/1993CA2132446A1 Novel barbiturate derivatives and protein and polypeptide barbiturate derivative conjugates and labels
1 ... 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 ... 1823